Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. - Wikidata - awgldk - TriplyDB

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

http://www.wikidata.org/entity/Q41222268

about

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective Management of hepatitis c genotype 4 in the liver transplant setting Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment KASL clinical practice guidelines: management of hepatitis C Sofosbuvir treatment and hepatitis C virus infection Advances in hepatitis C therapy: What is the current state - what come's next?Treatment strategies for chronic hepatitis C prior to and following liver transplantation Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance Impact of new treatment options for hepatitis C virus infection in liver transplantation Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline The new era of hepatitis C virus therapy Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C Hepatitis C virus infection.Screening and surveillance for hepatocellular carcinoma: perspective of a new era?Comparison of hepatocellular carcinoma in Eastern versus Western populations.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.Hepatitis C in a New Era: A Review of Current Therapies

P2860

Q26740216-D578972C-DCD2-4177-A0EE-E5E20DD1BB4E Q26740313-3F0283A3-8D79-49B1-9869-871C8A301AAE Q26740319-90C12C9B-AD2E-42FB-952F-3BD919FBE1D1 Q26745769-6F5F4E99-00D2-4CDE-9688-BC58A7D4B2CF Q26746910-E2AAAB85-353F-4812-BDF6-AC9A02818773 Q26749326-15FACDAA-86C4-4FC1-A6B6-2B56A8C05343 Q26751452-5D3B97E4-90A8-41D7-A526-DEF2CF08CB2F Q26752471-29A444A4-2597-4FB1-924A-B45796352E33 Q26770024-0E88E554-E9A4-4203-B1CB-AD0CEB65A6A4 Q26770036-EAE2B800-9BBF-4F09-9A76-873C272AB55A Q26771244-9D57EF6F-2D61-4C45-A155-DBB2E661B8E7 Q26773201-2D280540-A490-4D81-8A22-EEBD8E2888C1 Q26777086-6FD6165E-5812-4BFC-A720-9565A65F32C7 Q26781331-A9973AAE-894C-477D-93B9-269DE9BB5F29 Q26782017-E0FC155F-05B1-403F-8BC9-1958D5DA5D40 Q26795750-C3F575FC-B070-4082-8EB6-B9DB85472492 Q26801828-5FEF5838-F8FD-4A6D-B48D-768A746071FF Q28070260-C5BFC3FD-ED2F-4E9F-8911-21A5DE5AE2DC Q28070280-96178A75-4B9D-4394-A54E-61951B793C96 Q28073100-476E0A71-7079-4E3D-9AA4-ACB0CD695938 Q28074783-121E8AE1-DCD8-4217-A0FF-3CA68F027FB2 Q28075544-CA37B73A-EE3A-4BE2-B336-797C4A664C44 Q28076883-0A9BA23D-6BC2-4289-8217-6B7C133AEF57 Q28086947-92723AB7-ED1A-4D32-9535-DC755BA18AE7 Q30235178-814ED592-3FA6-4FD0-AE0E-B1A3A20D240E Q30235491-441BE63E-7BC0-429D-9256-115BE3F72CE2 Q30244651-A49199D4-689F-45FB-8219-91E2103C02A3 Q30245396-5435BFB6-D814-4527-9043-ECF8F249504D Q30250096-14F5740B-2930-42C8-B041-E07B87321D43 Q30250322-6E262D17-1B3F-4800-AE8D-72D3C5DE7612 Q30251763-5905E2E3-E1F3-4C00-9E58-734BE4A8B6EC Q30355190-C5035C5F-E573-49CC-96E6-7386340FFA1C Q30399476-70677793-CCD3-4EE1-8D5E-E58C9860D05C Q30841159-5E709768-28BB-491C-9B9F-53C9DE2ED9F7 Q31160142-131F545F-B160-4CB8-9A17-BC3AF2257349 Q31170657-9EC80E20-8629-4B9B-91A8-7CEA4BAFC126 Q33426112-D7F36528-676F-4753-A62B-7AB3DE89930E Q33435950-33FA7731-E3A0-4D71-A683-1331D33C7ABF Q33557819-67B4C87F-1C9A-4565-8E46-5B3E90CF8633 Q33585021-C2D8F14D-5932-416C-A5BA-8E0A6A04E110

P2860

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

http://www.wikidata.org/entity/Q41222268

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ledipasvir and Sofosbuvir Plus ...... s With Advanced Liver Disease.

@en

type

label

Ledipasvir and Sofosbuvir Plus ...... s With Advanced Liver Disease.

@en

prefLabel

Ledipasvir and Sofosbuvir Plus ...... s With Advanced Liver Disease.

@en

P1433

Q41222268-49A4F090-508B-46A2-99DC-88777AB4D96B

P1476

Q41222268-90F2FDB8-55B8-4FF8-82B1-11A3307176FD

P2093

Q41222268-048E2985-F501-4AD4-9447-30484DE4CBD8

Q41222268-0B9783D8-725B-4B6D-A450-564A58D93066

Q41222268-13A428E4-AFE4-4B7F-A7D4-D7C6780B1E3F

Q41222268-1E6874F7-55A8-4549-B843-AC84407B9B5F

Q41222268-2768F119-2D7E-44AE-A404-E3FC2DA80F74

Q41222268-2EEFB249-9CA7-4EA2-ADFB-5BC727924227

Q41222268-3516D109-2C23-4E03-9D4C-BB06BC035686

Q41222268-3EFBFDC2-F12C-45C8-8DFC-0F0275D0E841

Q41222268-48CF00AD-A93D-49E0-8101-E8227F2347EB

Q41222268-48CF88DC-B3D3-438D-B0C1-B07FE3E75DD9

P304

Q41222268-D05EFC45-1E91-4455-A385-B2CD3312EBF3

P31

Q41222268-BD07D904-CBA0-4025-8FE9-04C79A611BE9

P356

Q41222268-0EB4A7A0-1664-404C-B8E9-8E3165D5A613

P407

Q41222268-972D9CB8-C181-4FE9-AE8B-074BB01292D8

P433

Q41222268-0B947B99-49D9-4873-B762-2C5266978126

P478

Q41222268-DB4BC74A-BA22-45F6-BF37-B1EF7E3EF2DA

P50

Q41222268-41DB1821-2221-4AE1-A121-B2A1D801ED68

Q41222268-45DC45A9-E58D-47CE-BA75-D3D16F083D47

Q41222268-7CBC974A-E9F5-4934-96A9-8565D9BCB00E

Q41222268-A9BF85C9-85F6-45E4-8660-41E5A7BDD067

Q41222268-BE2E9BE5-2E4D-436E-B882-40650175124E

Q41222268-EA1AEA6A-34BD-4065-ACE4-AB59C08516D4

P577

Q41222268-0792365A-02BE-47B9-9913-9744D378645C

P5875

Q41222268-1DF11031-2803-4134-A97E-C744ED549936

P698

Q41222268-C0F3F9B2-8104-45BC-A01F-CE2792125AA8

P921

Q41222268-B63736B8-AA39-44F5-89EF-65FED644F41D

P356

J.GASTRO.2015.05.010

P1433

Gastroenterology

P1476

Ledipasvir and Sofosbuvir Plus ...... s With Advanced Liver Disease.

@en

P2093

Andrew J Muir

http://www.w3.org/2001/XMLSchema#string

Eugene Schiff

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

Hadas Dvory-Sobol

http://www.w3.org/2001/XMLSchema#string

Jacqueline G O'Leary

http://www.w3.org/2001/XMLSchema#string

Jill Denning

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Kevin M Korenblat

http://www.w3.org/2001/XMLSchema#string

Kimberly Brown

http://www.w3.org/2001/XMLSchema#string

Kymberly D Watt

http://www.w3.org/2001/XMLSchema#string

P304

649-659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2015.05.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

149

http://www.w3.org/2001/XMLSchema#string

P50

Hadas Dvory-Sobol

Charles S Landis

K. Rajender Reddy

P577

2015-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277083394

http://www.w3.org/2001/XMLSchema#string

P698

25985734

http://www.w3.org/2001/XMLSchema#string

P921